Research & Development
Gelrin© is a regenerative hydrogel platform originally developed at the Technion - Israel Institute of Technology by Prof. Dror Seliktar. Regentis Biomaterials is focused on utilizing this patented biosynthetic hydrogel as a platform technology to develop groundbreaking treatments for patients.
Regentis is currently using the platform technology to deliver the following product to the market:
GelrinC hydrogel implant for cartilage injury – Regentis Biomaterials
In addition, Regentis Biomaterials is actively involved in collaborations to research potential applications for the Gelrin platform, including:
Biodesign, a strategic alliance of global experts developing medicines that stimulate tissue regeneration. This coalition is supported by the European Commission as part of the Seventh Framework Programme (FP7).
This technology has potential as a development platform for diverse innovations to address real clinical needs. Regentis is committed to partnering with life science companies to develop additional clinical applications. If you are interested in partnering with Regentis Biomaterials, please send an email to email@example.com.